LEADER 01141nam0 2200301 450 001 000040229 005 20150121094904.0 010 $a2-251-00092-5 100 $a20150121d1987----km-y0itaa50------ba 101 2 $agrc$afre 102 $aFR 200 1 $aLettres et fragments$fDémosthène$gtexte établi et traduit par Robert Clavaud 210 $aParis$c<> belles lettres$d1987 215 $a184 p.$d20 cm 225 2 $aCollection des universités de France 300 $aTraduzione francese con testo greco a fronte 410 0$12001$aCollection des universités de France 500 11$aEpistulae / Demosthenes$919947 676 $a886.01$v(22. ed.)$9Lettere greche classiche. Origini-500 ca 700 0$aDemosthenes$f<384-322 a.C.>$0167473 702 1$aClavaud,$bRobert 801 0$aIT$bUniversità della Basilicata - B.I.A.$gREICAT$2unimarc 912 $a000040229 996 $aEpistulae$919947 997 $aUNIBAS CAT $aEXT013$b01$c20150121$lBAS01$h0949 FMT Z30 -1$lBAS01$LBAS01$mBOOK$1BASA1$APolo Storico-Umanistico$2GEN$BCollezione generale$3Class/400$680889$5L80889$820150121$f02$FPrestabile Generale LEADER 04407nam 22005655 450 001 9910483046003321 005 20230222190429.0 010 $a3-030-50287-2 024 7 $a10.1007/978-3-030-50287-4 035 $a(CKB)4100000011469456 035 $a(MiAaPQ)EBC6357285 035 $a(DE-He213)978-3-030-50287-4 035 $a(PPN)259931586 035 $a(EXLCZ)994100000011469456 100 $a20200924d2021 u| 0 101 0 $aeng 135 $aurnn#008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCancer Immunology $eBench to Bedside Immunotherapy of Cancers /$fedited by Nima Rezaei 205 $a2nd ed. 2021. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2021. 215 $a1 online resource 300 $aIncludes index. 311 $a3-030-50286-4 311 08$aErscheint auch als Druck-Ausgabe 9783030502867 327 $aFrontiers in Cancer Immunotherapy -- Novel Strategy of Cancer Immunotherapy: Spiraling Up -- Novel Prognostic Biomarkers for Personalized Cancer Treatments -- Tumor Antigen and Epitope Identification for Pre-Clinical and Clinical Evaluation -- Strategies to Target Tumor Immunesuppression -- Immune Modulation of Drugs in Prevention and Treatment of Cancers -- Overcoming Immune Tolerance With Immune Checkpoint Blockade -- Gene therapy and Virus-Based Cancer Vaccines -- Cancer Stem Cells: Biology and Potential therapeutic Applications -- Hematopoietic Stem Cell Transplantation and Lymphodepletion in Treatment of Cancers -- Combination of Chemotherapy and Cytokine Therapy in Treatment of Cancers -- T Cell Immunotherapy: From Synthetic Biology to Clinical Practice -- Role of Gamma-Delta T Lymphocytes in Cancer Immunosurveillance and Immunotherapy -- Adoptive T Cell therapy: Optimizing Chemokine Receptor-Mediated Homing of T Cells in Cancer Immunotherapy -- Cellular therapy of Cancer With B Effector Cells -- Monoclonal Antibodies for Treatment of Cancers -- Pattern Recognition Receptors in Cancers and Immunotherapy by Triggering or Targeting of Toll Like Receptors Pathway -- Recent Advances in the Use of NK Cells Against Cancer -- Dendritic Cell Vaccines for Cancer Therapy: Fundamentals and Clinical Trials -- Tumor Associated Macrophages and iNOS in Cancer Immunotherapy -- Photodynamic therapy and Anti-Tumor Immune Response -- Polarization of Tumor Milieu: Therapeutic Implications -- Immunotherapies Targeting 5T4 Oncofoetal Glycoprotein -- Immune Monitoring During Clinical Development of Anti-CTLA-4 Antibody Therapy -- PD-1 Blockade in Cancer Therapy -- New Advances in Radioimmunotherapy for the Treatment of Cancers -- Psychoneuroendocrinoimmunotherapy of Cancers -- Ethical Considerations in Cancer Immunotherapy. 330 $aThis translational, clinically oriented book describes in detail novel approaches to cancer immunotherapy, current strategies to target tumor immunosuppression, and prognostic biomarkers for personalized cancer treatments. Since the first, very successful edition of the book was published in 2015, the original chapters have been significantly updated and entirely new chapters are included on, for example, cancer immunoprevention, aptamer-mediated cancer gene therapy, haploidentical bone marrow transplantation for pediatric malignancies, and nanoimmunotherapy. The book is published as part of the three-volume Springer series Cancer Immunology, which aims to provide an up-to-date, clinically relevant review of cancer immunology and immunotherapy. Other volumes in the series address the translational medicine context and cancer immunotherapy for organ-specific tumors. Cancer Immunology: Bench to Bedside Immunotherapy of Cancers will be of special value to clinical immunologists, hematologists, and oncologists. . 606 $aOncology 606 $aImmunology 606 $aInternal medicine 606 $aOncology 606 $aImmunology 606 $aInternal Medicine 615 0$aOncology. 615 0$aImmunology. 615 0$aInternal medicine. 615 14$aOncology. 615 24$aImmunology. 615 24$aInternal Medicine. 676 $a616.994079 702 $aRezaei$b Nima 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910483046003321 996 $aCancer Immunology$91760493 997 $aUNINA LEADER 01226nas 2200421- 450 001 9910446858903321 005 20250320153501.0 011 $a1741-2730 035 $a(DE-599)ZDB2118686-8 035 $a(OCoLC)50517007 035 $a(CKB)111027537850004 035 $a(CONSER)--2020207501 035 $a(EXLCZ)99111027537850004 100 $a20020831a20029999 s-- a 101 0 $aeng 135 $aurmnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aEuropean journal of political theory $eEJPT 210 1$a[Thousand Oaks, Calif.] :$cSage Publications,$d2002- 300 $aRefereed/Peer-reviewed 311 08$a1474-8851 517 3 $aEJPT 606 $aPolitical science$vPeriodicals 606 $aPolitical science$zEurope$vPeriodicals 606 $aPolitical science$2fast$3(OCoLC)fst01069781 607 $aEurope$2fast 608 $aPeriodicals.$2fast 608 $aPeriodicals.$2lcgft 615 0$aPolitical science 615 0$aPolitical science 615 7$aPolitical science. 676 $a320 906 $aJOURNAL 912 $a9910446858903321 996 $aEuropean journal of political theory$91065303 997 $aUNINA